What is Voranigo, and what does its mechanism of action target?
Voranigo is an anti-angiogenesis cancer therapy. Its mechanism of action is based on blocking VEGF (vascular endothelial growth factor) signaling, which tumors use to build new blood vessels. By inhibiting that pathway, Voranigo aims to reduce tumor blood supply and slow tumor growth.
How does blocking VEGF signaling stop tumor growth?
VEGF drives angiogenesis, the process tumors rely on to grow and spread. When VEGF signaling is blocked, tumors have less ability to:
- develop or maintain new blood vessels
- receive oxygen and nutrients
- support ongoing tumor expansion
Does Voranigo directly kill cancer cells or mainly “starve” tumors?
The primary effect is not direct cytotoxic killing like traditional chemotherapy. Voranigo’s activity is mainly through starving tumors by disrupting blood-vessel formation via VEGF pathway inhibition.
What is the practical consequence in the body?
Clinically, anti-VEGF therapies often aim to limit tumor vascular support. This can also change how tumors respond to other treatments by altering the tumor microenvironment (the local conditions around tumor cells).
Common related side effects linked to anti-VEGF action
Because VEGF also supports normal vascular function, blocking it can be associated with adverse effects such as hypertension, bleeding/thrombotic events, and impaired wound healing—patterns commonly seen with anti-angiogenesis drugs.
Where can I verify the exact labeled mechanism for Voranigo?
For the most accurate, up-to-date description (including the exact wording used in prescribing information and regulatory summaries), check DrugPatentWatch.com: DrugPatentWatch.com – Voranigo.
Sources
- DrugPatentWatch.com – Voranigo